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Summary 
Many people still die of tuberculosis (TB). One-third of the world’s population is 
infected with M. tuberculosis, and the poor suffer most. More than 95% of TB cases and 
deaths are in developing countries and TB is closely linked to poverty. The prevalence 
of TB increases globally, mainly because of the worsening HIV pandemic. Emerging 
drug-resistant TB poses another challenge to efforts to control TB. In 1991, the World 
Health Organization (WHO) introduced a comprehensive approach to TB control, 
eventually called DOTS- directly observed treatment, short course. Later WHO declared 
TB a global emergency. 
 
Ethiopia is one of the 22 TB high-burden countries in the world. DOTS was adopted in 
the first half of 1990s in a few pilot sites, and later expanded. As a result, in 2003, the 
TB control programme used DOTS in 95% of the public health institutions in the 
country.  
 
This thesis investigates some elements of DOTS and how these were carried out. The 
studies focus on epidemiological trends, operational challenges and opportunities to 
improve TB case finding and treatment outcomes in rural Ethiopia. The aim of the 
thesis is to assess trend in TB control efforts, estimate the burden of TB, address 
operational challenges and explore alternative approaches to improve TB case detection 
and treatment outcomes in rural Ethiopia. The studies were conducted in Hadiya in 
southern Ethiopia. We used cross-sectional, longitudinal observational and intervention 
study designs. The studies were conducted in rural communities and in public health 
institutions. Most of the papers focus on smear-positive TB, the most infectious form of 
TB. 
 
The study findings show that after five years, the DOTS population coverage reached 
75%. Simultaneously, case notification and treatment outcomes of TB patients 
improved.  Between 1994 and 2000, the treatment success for smear-positive TB rose 
from 38% to 73%. With a decline in treatment failure and default rates, the steadily 
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increasing trend in treatment success suggests expanding DOTS led to a significant 
improvement in treatment outcomes.  
 
Trends in case notification and treatment outcomes represent proxy indicators for 
programme performance. However, to better evaluate the impact of a TB programme, 
we need both baseline and follow-up data on disease prevalence and incidence. 
Considering the shortage of resources, we used a simple and less expensive method to 
estimate the prevalence of smear-positive TB in a rural community. The results show 
that for every two case of smear-positive TB on anti-TB treatment, there was one 
undiagnosed infectious case in the community. Such a method of estimating TB burden 
in a population may bridge the information gap on the extent of TB in resource-
constrained settings where case-notification data are incomplete and more sophisticated 
approaches of estimating incidence and prevalence are not possible. 
 
An intervention study on case finding through a village outreach programme showed 
the intervention was effective in improving the speed of case detection for smear-
positive TB. Though not statistically significant, our study shows a higher case 
notification rate in the intervention communities compared with the control 
communities. Patients in both groups had comparable treatment outcomes. This case 
finding method may be relevant for the new health extension programme in the country 
that gives due emphasis to community-based approaches. The effectiveness of such an 
intervention and its cost-effectiveness warrant further investigation.  
 
Improved case detection has a meaning only when the detected cases successfully 
complete the treatment. This study explored possible causes predicting treatment non-
completion among smear-positive pulmonary tuberculosis patients. One in five patients 
did not complete the treatment and the limiting factor was access to treatment. As most 
treatment interruption occurred during the continuation phase of TB treatment, 
clinicians in the TB programme should hold follow-up discussions with patients to 
ensure treatment compliance in this phase.  
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Building diagnostic competence is a precondition to improved case finding. Evaluation 
of routine sputum microscopy for acid-fast bacilli at the diagnostic laboratories over 
three-year period revealed a declining trend in false readings and 97% overall 
agreement between the readings at the diagnostic laboratories and that in the reference 
laboratory. Unfortunately, the number of laboratories taking part in such quality 
assessment scheme declined, signalling a need to revitalise and scale-up the quality 
assessment service in the region.  
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1.  Introduction 
1.1 Tuberculosis: historical outline 
Tuberculosis (TB) has claimed countless lives through centuries. Current advances in 
molecular techniques have enabled the discovery of tuberculosis from mummified 
remains and bone samples 1-5. In line with these findings, some authors have suggested 
there may be biblical references to TB from the Old Testament books dating to a time 
when the Israelites lived in Egypt 6. Well-documented evidences of large-scale human 
suffering from this deadly disease, however, date back to the past three centuries. The 
incidence of TB in Europe and North America increased during the industrial revolution 
in the 17th and 18th centuries. Since then, there has been a decline in TB prevalence in 
these countries, mainly because of improved socio-economic conditions 7, 8. 
 
Even if TB was recognised during the time of Hippocrates (460-377 BC) as ¨phthisis¨ to 
describe its gradual wasting nature, the origins of TB remained unknown until 1882, 
when Robert Koch identified the causative agent, Mycobacterium tuberculosis. This 
historic breakthrough was followed by the development of acid-fast stain (AFS) 
technique in 1885. When Röntgen in 1895 discovered the x-ray, the capacity to 
diagnose and understand its pulmonary manifestations was improved 7.  Research 
during the first half of the 20th century led to the discovery of BCG vaccine in 1921 and 
two chemotherapeutic agents, streptomycin and para-aminosalicylic acid (PAS) in 1944. 
More effective treatment and control of the disease using combined chemotherapy 8 
followed the discovery of Isoniazid and other anti-TB drugs in the 1950s and 1960s .  
 
1.2 Transmission and course of infection 
TB is caused mainly by M. tuberculosis, and occasionally by other organisms of the 
Mycobacterium tuberculosis complex- M. bovis, M. africanum, M. canetti and rarely, 
M. microti 9.  The most important source of infection is a person with smear-positive 
pulmonary TB (PTB). Untreated active smear positive PTB case will infect an average 
of 10-15 people per year 10. The tubercle bacilli cannot survive direct sunlight exposure 
for more than five minutes, but can survive in the dark for long periods 11, which means 
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that transmission usually occurs indoors. The extent of exposure to the droplet nuclei 
(duration and dose) and the susceptibility of the host determine an individual’s risk of 
infection 12. M. bovis is also transmitted through ingestion of raw-milk containing the 
bacilli.  
 
Primary infection occurs when a person is newly exposed to tubercle bacilli. Droplet 
nuclei that are tiny enough to escape the mucocilliary defence of the bronchi, lodge in 
the terminal alveoli of the lungs and begin to multiply forming a lesion called Ghon 
focus.  The Ghon focus and related hilar lympadenopathy form a primary complex. 
Usually the immune response (delayed type hypersensitivity and cellular immunity) 
controls multiplying bacilli, resulting in a latent infection with a few dormant bacilli. In 
such cases, the only evidence of infection may be a positive tuberculin skin test. In 5% 
of the cases, the bacilli overwhelm the immune response and multiply resulting in a 
primary TB within a few months to a maximum of 5 years 13. Post-primary TB occurs 
when the latent infection is reactivated or when the individual is reinfected 14-16. Post-
primary TB is characterised by extensive tissue destruction and cavitation, and mainly 
affects the lungs but can also involve other organs 11. 
 
Among infected individuals, the lifetime risk of developing active TB is 5-10% 17. 
However, the risk may be as high as 50% among immune-compromised individuals 
such as those infected with HIV 11. Among untreated PTB patients, 50% die within 5 
years, 25% will be spontaneously cured and 25% will remain with chronic infectious 
TB.   
 
1.3 Global situation of tuberculosis 
It is unfortunate that more than a century after the discovery of the infectious agent and 
five decades after introducing effective chemotherapy, tuberculosis remains a major 
cause of death in the world. One-third of the world’s population is infected with M. 
tuberculosis, and the socio-economic outcomes of the disease are huge 10, 11, 17-19. While 
the incidence has increased in poor countries, the increase of TB was also noted in some 
industrialised countries that had successfully lowered its incidence and prevalence 20-22. 
In 2000, there were 8.3 million new cases and 1.8 million deaths from TB19. In 2002, 
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the figures were estimated to have increased to 8.8 million new cases and over 2 million 
deaths 22. More than 95% of TB cases and deaths are in developing countries where TB 
accounts for 7% of all and 25% of avoidable adult deaths 19, 23.  The annual rate of 
increase in the number of TB cases was 1.8% between 1997 and 2000, whereas the 
increase was 6.4% in sub-Saharan Africa 19. TB accounts for 2.8% of global disability 
adjusted life years lost (DALY)1 in all age groups and 7-8% of all DALYs among those 
15-49 years 24-26. Thus, TB is a major public health concern, ranking 7th as a cause of 
global DALYs. The unfortunate paradox between the scientific advances in the 
diagnosis and treatment of the disease and the ever-inclining TB burden is yet to be 
resolved.   
 
The HIV epidemic has fuelled the TB epidemic in low-income countries. HIV infected 
people are at increased risk of infection with TB, activation of a latent infection, rapid 
progression of active disease, and TB deaths 19, 27-29. People infected with HIV are 10 
times more likely to develop active TB compared to persons not infected with HIV 11. 
Worldwide, 9% of new TB cases in adults and 12% of deaths from TB in 2000 were 
attributable to HIV. The matching proportions in sub-Saharan Africa were 31% and 
39% respectively 19. Although the long-term prospect may be seen with some optimism, 
the high HIV prevalence makes any TB control effort difficult 7, 30-35. 
 
Other conditions leading to TB include immunological factors (chronic illnesses, 
immuno-suppressive therapy, stress), malnutrition, environmental (overcrowding, 
repeated and prolonged exposure to TB bacilli), poverty, war, famine and displacement 
36-38. While anyone can get TB, the poor shoulder the greatest burden 39. If inequalities 
in resources and health care provision are not addressed, it is difficult to eliminate TB as 
a global health threat 7, 20, 33, 36-39.  
 
Emerging drug-resistant TB, especially multidrug resistant TB (MDR-TB) poses 
another challenge of reducing human misery from this deadly disease 40-42. In poor areas 
with many MDR-TB cases, extra cost of second-line drugs is a huge burden to the 
already underfinanced national TB programmes 43, 44. Even if available, these drugs can 
                                                          
1DALYs from a condition refer to the sum of years of life lost because of premature mortality and years 
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only be used under close monitoring within a strong TB programme 45.  Efforts have 
been made by the WHO and its partners to address the issue of  “market failures” in 
getting the drugs, and to strengthen the TB programmes as a condition to tackling 
MDR-TB 44, 46, 47.  Despite an encouraging progress, the battle remains far from over 47-
49. 
 
1.4 Control efforts and targets 
Over the past 50 years following the landmark discovery of anti-TB chemotherapeutic 
agents for combined treatment, the prime question was how the control efforts should 
be organised. The choice of the control strategy during these years was largely linked to 
the overall development of health infrastructure especially in the developing world. As a 
result, the strategy had to switch-off between the specialised vertical and more 
integrated horizontal approaches, but at large lacked uniformity. In 1991, the World 
Health Organization (WHO) introduced a comprehensive approach to TB control based 
on several reports that showed success in dealing with this global scourge in developing 
set-ups 17, 50-54. The approach subsequently took a shape that was widely and 
enthusiastically accepted and named DOTS- directly observed treatment, short course. 
 
The continuing seriousness of the epidemic in many parts of the world prompted WHO 
to take an unprecedented step of declaring TB a global emergency. The director of the 
global TB programme stated that “the growing tuberculosis epidemic is no longer an 
emergency only for those who care about health, but for those who care about justice” 
55. The declaration was soon followed by the adoption of the DOTS strategy, the WHO-
recommended global strategy for TB control. The five pillar elements of the DOTS 
strategy are: political commitment to national TB control programmes; detection of 
infectious cases through sputum smear microscopy; standardised case management 
using short-course chemotherapy under direct supervision at least during the intensive 
phase; uninterrupted supply of anti TB drugs; and proper registration, record keeping 
and reporting mechanisms including follow up of treatment outcomes 56. 
 
                                                                                                                                                                          
of life lived with disability, adjusted for the severity of disability. 
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Many favour DOTS as one of the most cost-effective of all health interventions 25, 26, 57. 
Global reviews as well as reports from some developing countries also had favourable 
implications for this strategy 58-60. DOTS is equally important in curing TB patients with 
HIV co-infection and therefore, its importance in the era of the HIV/AIDS epidemic 61, 
62. Despite its promising prospect, less than 50% of estimated smear-positive TB cases 
were treated under the DOTS in 2003 22. 
 
The global response to the emergency has been scaled up since recently 63 64. The aim 
was to intensify actions to reach the global targets of 70% TB case detection and 85% 
treatment success for those detected by the year 2005, and to halve the global TB load 
by the year 2010. The final goal was to remove TB as a global public health problem by 
the year 2050 65. To overcome obstacles and strengthen gains in TB control, WHO aims 
at ensuring proper diagnosis and treatment of all TB patients under programme 
conditions 66, 67. Simultaneously, the two major constraints in the control of TB- 
TB/HIV 34, 68, 69 and MDR-TB 45-47, 70-72, have been addressed as important elements of 
the control effort. 
 
Five targets of the millennium development goals (MDG) are concerned with TB. By 
2005 the world community aimed to identify 70% of new infectious cases and 
successfully treat 85% of these cases; by 2015, to have halted and begun to reverse 
incidence; between 1990 and 2015, to halve TB prevalence and death rates 22. However, 
some of these targets are met with challenges from the outset. For example, case 
detection under the DOTS in 2003 was reported to be 45% globally, and it might 
increase to 60% in 2005, 10% lower than the target 22, 32. Some fear that it might take 
nearly a decade after 2005 to reach the 70% target 73. Similarly, decline of TB 
incidence, prevalence and death to the target set for 2015 may hardly be achieved in 
Africa and probably in Eastern Europe 32. Treatment success rates in these regions are at 
the range of 71-75%, way below the 85% target 32. Based on programme conditions, 
alternative mechanisms for intensified case-finding and increased favourable treatment 
outcomes should be sought. Decentralisation of DOTS, community-based case finding 
and treatment, and private-public partnerships in the TB control have shown better 
results in low-income settings 74-82. 
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2. Tuberculosis in Ethiopia 
2.1 The country 
Ethiopia, one of the oldest civilisations in the world, is also the oldest independent 
country in Africa. With an area of 1.13 million square kilometres, Ethiopia shares 
borders with Kenya, Somalia, Djibouti, Eritrea and Sudan. 73 million people live in the 
country 83, making it the second most populous country in Africa.  Over 85% of the 
population are rural. The major economic base is agriculture that accounts for half of 
the gross domestic product (GDP) and 80% of total employment. The current annual per 
capita income is about US$ 100.  
 
Topographically Ethiopia is divided into the central highland plateau, the rift valley and 
the coastal lowland areas. The Great Rift Valley that crosses the country from its 
northeastern border to its southern border with Kenya, divides the high plateau with 
central mountain range into two.  The elevation ranges from 125 metres below sea level 
at Danakil Depression to 4,620 metres above sea level at mount Ras Dashen. Most of 
the population lives in the highlands on subsistence farming, whereas pastoralist 
populations live in the lowlands. The climate is mainly tropical with wide variations and 
frequent irregularities resulting in repeated periods of drought and famine. 
 
The Ethiopian monarchy ended in 1974 when the military junta set up a socialist state. 
During 1974-1991, the country operated a central command economy under the military 
dictatorship. The regime was overthrown in 1991 by the Ethiopian Peoples’ 
Revolutionary Democratic Front (EPRDF). A new constitution was adopted in 1994 and 
the fist multi-party election was held in 1995. Currently, Ethiopia has a federal 
democratic government with nine ethnic-based regional states and two city 
administrations, and operates as a market-oriented economy.  
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2.2 Health care delivery and health-related problems 
The health service coverage, defined as part of population living within reach of a 
health institution in two-hour walking distance, is estimated to be 51% 84. The major 
health problems of the country are communicable diseases. Reports suggest the leading 
causes of outpatient morbidity are malaria, helminthiasis, acute respiratory infections, 
dysentery, tuberculosis and pneumonia.  In 2000, TB was the fifth major cause of 
morbidity and the second major cause of admissions to hospitals 84. The estimated HIV 
prevalence in 2003 was 4.4%, of which 12.6% was urban and 2.6 rural 85. Table 1 
shows some health and demographic indicators. 
 
The current government’s health policy aims to improve the access to and quality of 
health services. Priority is to prevent and control communicable diseases, improve the 
health infrastructure, develop manpower and strengthen public and private sectors in 
providing health care 86, 87. The government set up a four-tier referral system with a 
health centre and its five health posts at the base of the pyramid and referral teaching 
hospitals at the top.  To improve access to health care, the government launched a new 
community-based approach, the health extension package. Under this initiative, well-
trained and paid health extension workers live and work within the communities to 
promote supportive health behaviour and bridge the community health outreach 
activities. 
 
Table 1: Selected Health-related and demographic indicators for Ethiopia  
Estimate   
Year Ethiopia SNNPRS* 
Crude birth rate per 1000 2004 42 44 
Crude death rate per 1000 2004 18 18 
Annual population growth rate (%) 1992-2002 2.8 2.9 
Life expectancy at birth (years) 2002 48 46 
Total fertility rate 2002 6.2 5.8 
Infant mortality rate per 1000 live births 2000 112 113 
Under-5 Mortality rate per 1000 live births 2000 179 191 
Maternal Mortality ratio (per 105 live births) 2000 850 - 
% population using adequate sanitation 2004 6 12 
Adult HIV prevalence rate (15-49 years) 2005 4.4 - 
Adult literacy rate, per 100 2000 39 - 
*Southern Nations, Nationalities and Peoples’ Regional State of Ethiopia 
Source: UNICEF88, WHO89 and CSA90 
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2.3 Tuberculosis control efforts 
Ethiopia is one of the top 22 TB high-burden countries in the world with an estimated 
annual incidence of 356 cases per 100,000 22. The smear-positive PTB incidence is 
155/100,000. In 2001, the national TB and leprosy control programme (NTLCP) 
registered 94,957 TB cases from DOTS areas, representing case notification rates of 
173 and 60 per 100,000 population, for all forms of TB and for new-smear positive 
PTB, respectively 91. In 2005, a total of 126,233 TB cases were notified to the NTLCP, 
of which 38,800 (31%) were smear-positive PTB cases. Among adults aged 15-49 
years, an estimated 21% of TB cases are HIV-positive, with a great variation among 
rural and urban areas ranging from 15% to 40% 22, 91, 92.  
 
TB control efforts in Ethiopia date back to the early 1960s, when a few TB centres and 
sanatoriums were set up in some urban settings. These efforts were not well co-
ordinated until 1976 when the national TB control programme office was established 91. 
However, the programme had staff and budgetary constraints. In the early 1990s, the 
NTLCP was reorganised to strengthen the regional TB programme units and integrate 
the programme into the general health services. In the meantime, the TB and leprosy 
programmes were merged to form a single programme.  
 
The DOTS strategy was adopted in the first half of the 1990s in a few pilot sites, and 
eventually scaled up. In 2003, 95% of the health facilities in the country worked under 
the DOTS 22. The major partners in carrying out DOTS in the country are the 
government of Ethiopia, WHO, the Global Fund, the Royal Netherlands Tuberculosis 
Association (KNCV), the German Leprosy and TB Rehabilitation Association (GLRA) 
and the US government (USAID and CDC). 
 
 2.4 The rationale for the study  
The goals of TB control are to reduce morbidity, mortality and transmission and to 
prevent drug resistance. Well-planned TB control programme may lead to these goals 36, 
93. However, TB programmes often suffer from shortage of information necessary for 
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proper planning and evidence-based decision making. We have limited data from rural 
Ethiopia on the burden of TB and on what portion of such cases have been detected and 
effectively treated. Lack of such information makes planning and monitoring of the 
control efforts difficult. Making scientifically sound baseline information and regularly 
analysing trends on morbidity, mortality, case-notification, sputum smear-conversion, 
treatment compliance and diagnostic quality assurance could help to fill the information 
gap. This study was done to bridge the gap. 
 
TB control efforts relate to the different stages in the pathogenesis and clinical course of 
TB infection. Figure 1 presents a schematic model of the pathogenesis and clinical 
course of TB and the study topics covered in the thesis.  As discussed earlier, the 
lifetime risk of developing active TB among infected individuals is one in ten (or more 
in case of HIV co-infection). Half of undetected and untreated TB cases die within five 
years, whereas one-fourth gets cured spontaneously and the remaining one-fourth 
continues to transmit TB to others. Early detection and treatment of cases may alter this 
course by increasing cure rate, decreasing death and chronic TB, and eventually 
minimising the extent of infectiousness. 
 
The study examines DOTS in the context of changes in the natural course of TB. Paper-
I addresses cross-cutting issues relevant to the different stages of TB: case-detection, 
registration for treatment, sputum-smear conversion and outcome of treatment. Paper II 
deals with estimating the load of TB, which in turn, is a reflection of the transmission 
within a community. Paper III presents an approach that might help to intensify case 
finding and reduce duration of infectiousness. One of the challenges after case detection 
is to ensure successful treatment completion. Paper IV looks into the problem of 
treatment non-completion and its potential determinants. The most feasible diagnostic 
tool in resource-poor settings for identification of new cases and for monitoring 
response to treatment is sputum-smear microscopy. Paper V deals with the quality 
assessment of sputum microscopic examinations at the diagnostic laboratories.  
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Non-infected
TB Infection
Disease development
Recognition of symptoms
Health care seeking
Getting a diagnosis
Treatment compliance
Treatment outcome
Post TB social consequences
Trends in case notification (Paper I)
Study topics (papers)
Case-finding through community outreach
(Paper III)
Quality control of sputum-smear
microscopy (Paper V)
Prevalence of smear-positive TB
(Paper II)
Predictors of treatment non-completion
(Paper IV)
Trends in treatment outcomes (Paper I)
Figure 1: A schematic model of the pathogenesis and clinical course of
tuberculosis in relation to the study topics covered in the thesis.
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The thesis, therefore, focused on the epidemiological trends, operational challenges and 
existing opportunities to improve TB case finding and treatment outcomes in rural 
Ethiopia. Both case detection and treatment success could be influenced by individual, 
social and biomedical factors 94-99. Low case detection may continue to be of concern as 
most TB programmes remain far short of the global target of 70% case detection 100-102.  
In the developing world, many TB patients live, transmit and die undetected 102, 103, and 
Ethiopia is not an exception. Low success in treatment completion is another and 
equally important challenge in most resource-constrained settings. Because of this, there 
is a need to study the trends in case notification and estimate case detection and 
treatment success rates (Paper I). 
 
Studies from sub-Saharan Africa report delays in case detection, ranging from 50 to 180 
days 96, 99, 104, 105.  Early detection of cases is key to reduce the duration of infectivity 
and thus, transmission of the bacilli 106. Intensified case-finding among household 
members of infectious TB cases is an effective approach in the early detection of 
cases107-109. However, in areas with high TB incidence, the main source of infection may 
be contacts outside the household 110, 111.  This warrants the need for a broader 
perspective in improving case-finding and lessening the duration of infectiousness 
within communities in high incidence settings 41. This thesis tries to address the issue. It 
tests the value of an alternative community-based approach in improving TB case 
finding and in shortening pretreatment symptom duration in a setting with low health 
service coverage (Paper III).  
 
There are few reports on the extent of TB from population-based surveys in Ethiopia. 
Most of the data come from health institutions, and such data often lack completeness 
and consistency. In resource-poor settings with low health service coverage, poorly 
developed diagnostic network and weak disease notification, estimating TB burden 
from case notifications is difficult. Neither is it possible to oversee the progress in TB 
control efforts from such data alone. Annual risk of infection (ARI) calculated from 
tuberculin survey gives a valuable estimate of TB incidence and prevalence 112. Another 
community-based approach for estimating TB prevalence is mass miniature radiography 
(MMR). However, these approaches are expensive and demand time and expertise. In 
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this thesis, an alternative approach, screening by symptom inquiry followed by sputum 
microscopy, is discussed (Paper II). 
 
 In resource-constrained settings where the health care services are not well developed, 
ensuring treatment adherence is another major challenge the TB programmes face 113.  
Treatment non-completion may increase the risk of drug resistance, relapse and death 
and may prolong infectiousness 114-116. Before introducing DOTS in Ethiopia, 82% of 
TB patients failed to complete treatment 117. Though a remarkable decline to 25% was 
noted after DOTS 118, it is still high.  The thesis analyses a 7-year trend in default rate as 
well as the extent and predictors of treatment non-completion among smear-positive TB 
patients in rural Ethiopia (Papers I & IV). 
 
This thesis also addresses how the DOTS programmes keep their record and monitor 
treatment outcomes. Thus, we investigated how complete the TB registers were and 
how often the TB clinics did follow-up smear examinations (Paper I). The thesis also 
presents an assessment on the quality control of sputum microscopy in southern 
Ethiopia (Paper V). Sputum microscopy is the main diagnostic tool for pulmonary TB. 
External quality assessment (EQA) helps to standardise sputum microscopy for 
detecting infectious TB in the diagnostic centres and to validate the reported AFB 
microscopy results from these centres. Evaluating the diagnostic laboratories had not 
been done and therefore, the need for the current study.  
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3. Objectives  
3.1 General objective 
The overall aim of the thesis is to assess trend in TB control efforts, address operational 
challenges and explore alternative approaches to improve TB case detection and 
treatment outcomes in rural Ethiopia. 
 
3.2 Specific objectives 
i. To assess the impact of DOTS expansion on the trends in case notification and 
treatment outcomes for tuberculosis over time (Paper I). 
ii. To estimate the prevalence of smear-positive pulmonary tuberculosis and burden 
of undetected TB in a rural community (Paper II). 
iii. To find out whether case-finding through community outreach in a rural setting 
has an effect on case-notification rate, pretreatment symptom duration, and 
treatment outcome of smear-positive pulmonary tuberculosis (Paper III).  
iv. To determine factors predicting treatment adherence among smear-positive 
pulmonary tuberculosis patients (Paper IV). 
v. To evaluate the agreement in the readings of sputum smears for acid-fast bacilli 
between the diagnostic and reference laboratories (Paper V).  
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4. Methods 
4.1 Description of the study setting 
The studies were conducted in the Southern Nations Nationalities and Peoples’ 
Regional State (SNNPRS). It is one of the ten regional states of Ethiopia with a 
population of 14 million and average population-density of 98 people per square 
kilometre. The region is unique for its composition of more than 45 indigenous ethnic 
populations each with its own linguistic and cultural identity. While pastoralist 
populations live in areas bordering Kenya and Sudan, the majority is settled rural 
population. The regional TLCP was set up when the national programme was 
reorganised in 1994. Before setting up the regional TLCP, vertically organised and 
centrally co-ordinated pilot TB control projects had been carried out in some zones with 
long- and unsupervised short-course chemotherapy. DOTS was introduced in 1996.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2: Map of Ethiopia showing the study area.
SNNPR
Hadiya
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Data for Papers I-IV are from studies conducted in Hadiya zone (Figure 1), one of the 
13 zones in SNNPRS. Paper V is based on data gathered on sputum samples collected 
from nine zones in the region, including Hadiya, for external quality control. The 
population of Hadiya is estimated to be 1.3 million 119, 120. Besides 15 TB diagnostic 
centres including the zonal hospital, five health centres and 21 health stations also 
provide treatment for TB patients referred or transferred from the diagnostic centres, 
thus making the number of treatment centres 41. All treatment units provide DOTS and 
report TB cases to the zonal and regional TLCP. 
 
4.2 Design and data collection 
Table 2 summarises the design and the study populations. Detailed study designs and 
sampling procedures are described in individual papers. Cross-sectional, longitudinal 
observational and experimental (field trial) study designs were employed. The studies 
were conducted within rural communities and in public health institutions. Most of the 
papers study smear-positive PTB.  
 
Table 2: Summary of study designs employed.  
Paper Topic addressed Design Study population Study period 
I DOTS expansion, case 
notification and treatment 
outcomes  
 
Retrospective 
trend analysis 
19971 TB patients 
registered between 
1994 and 2001 
  
Jul- Nov 2002
II Prevalence of smear-
positive tuberculosis 
 
Cross-sectional 
survey 
16697 adults surveyed 
in a rural district 
 
Feb 2003 
III Tuberculosis case finding 
through a village outreach 
programme 
 
Community 
randomised 
trial 
Thirty-two rural 
communities with a 
population of 353,000 
 
May 2003- 
Apr 2004 
IV Predictors of treatment 
adherence among smear-
positive tuberculosis 
patients 
 
Cohort study 404 smear-positive 
PTB patients 
diagnosed in a zonal 
hospital 
Sept 2002- 
Apr 2004 
V Quality control of sputum 
microscopic examinations 
for acid-fast bacilli 
Cross-sectional 
audit 
2,209 slides collected 
from nine zones in 
SNNPRS 
Oct 2000- Jun 
2002 
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In Paper I, we studied 19,971 tuberculosis patients registered for treatment in 41 
treatment centres in Hadiya zone between 1994 and 2001. The data were collected from 
the unit tuberculosis registers. For each patient, we recorded information on 
demographic characteristics, treatment centre, year of treatment, disease category, 
treatment given, follow-up and treatment outcomes. We also checked the year when 
DOTS was introduced to the treatment centre. We analysed the trends in case 
notification, follow up sputum-smear conversion and treatment outcomes along the 
course of DOTS decentralisation and expansion.   
 
Paper II employed cross-sectional study design to estimate the prevalence of smear-
positive PTB in adults. Using trained data collectors, we interviewed adults older than 
14 years by home-to-home visit, and asked for cough of two or more weeks with or 
without sputum, chest pain or difficulty of breathing. Symptomatic TB suspects gave 
three sputum samples for standard smear microscopy. The first specimen was collected 
during the interview, the second early in the following morning, and the third was 
collected when the data collectors revisited the house. Two experienced senior 
laboratory technicians examined the sputum smears for acid-fast bacilli (AFB) after 
standard Ziehl-Neelsen (ZN) hot staining technique 121. As a means of internal quality 
check, each slide was cross-read twice, by two independent technicians. 
 
Paper III is a community randomised trial. Thirty-two rural communities in two districts 
of Hadiya zone were randomly allocated to intervention or control groups. The sample 
size was determined using the formula that considers the coefficient of variation among 
communities (K), the power of the study, cluster size and the expected outcome 122. 
Health workers from seven health centres held monthly diagnostic outreach at 12 
intervention communities and got sputum samples from symptomatic tuberculosis 
suspects for sputum microscopy. Every month, before the outreach day, trained 
community promoters mobilised house-to-house and at popular gatherings, giving out 
TB leaflets and discussing symptoms of tuberculosis. Symptomatic individuals were 
encouraged to visit the outreach team or a nearby health institution. In the control 
communities, cases were detected through passive case finding among symptomatic 
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suspects reporting to the health institutions. New smear-positive TB patients living in 
the intervention and control communities and diagnosed during this period were 
prospectively enrolled in the study. The outcome measures were case notification rate, 
pretreatment symptom duration and treatment outcome (success, default, death) 91. 
Treatment success was defined as cure (smear-negative at treatment completion and on 
at least one previous occasion) plus treatment completion without confirmation by 
smear-microscopy. Default was defined as treatment interruption for more than eight 
consecutive weeks after a minimum of four weeks on treatment. Treatment failure was 
defined as remaining or becoming again smear-positive at five months or later during 
treatment. 
 
The fourth study (Paper IV) used a prospective longitudinal study design to find out 
predictors of treatment adherence among smear-positive tuberculosis patients diagnosed 
and registered for treatment in a zonal hospital. Using pretested questionnaire, potential 
predictor factors for defaulting from treatment were recorded at the beginning of 
treatment and patients were followed-up until the end of treatment. . Default rate in each 
stratum of the predictor factors was calculated against total person-time of observation. 
All defaulters were traced and interviewed regarding the main reason for defaulting 
from treatment. After the interview each defaulter was encouraged to get back to 
treatment at the nearest health facility of choice. 
 
The study on quality control of sputum microscopic examinations for AFB (Paper V) is 
a cross-sectional performance audit. The peripheral laboratories kept all positive slides 
and an equal number of negative slides (kept at dark places) until the zonal TLCP co-
ordinators collected the needed number of slides. The collected slides were rechecked 
by microscopists at the regional reference laboratory that were blinded to the readings 
of the smears at the diagnostic centres. Slides with discordant readings were reread at 
the central reference laboratory and the readings at the central laboratory were 
considered as the final result. 
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4.3 Data analysis and statistics 
We used SPSS for windows version 12.0.1 (SPSS inc., Chicago, IL) to analyse the data. 
Proportions with 95% confidence intervals were used to analyse categorical data. 
Univariate analysis with Odds ratio and Chi-square tests were used to compare different 
groups in studies I and IV, and to describe prevalence in study II. 
 
We analysed the data for study III on the basis that all symptomatic TB suspects in the 
intervention communities intended to use the community outreach services. The unit of 
randomisation and analysis in this cluster-randomised trial was the community. 
Weighted means of case detection rate, percentage symptomatic for >3 months, median 
duration of illness and treatment outcome (success, default, death) were compared using 
independent sample t-test and Mann-Whitney U test 123-125. The intracluster correlation 
coefficient (ICC) for each variable was calculated from the one-way ANOVA using the 
method suggested for estimating ICC from more than one group 123 and that for binary 
outcome variables 126. 
 
The independent effects of potential predictor variables on the outcome of interest 
(Adjusted OR, Adjusted HR) were assessed using a logistic regression model (Paper I) 
and Cox regression model (Paper IV), respectively. Sensitivity, specificity, predictive 
values, and proportions of false readings were compared using χ2 test and 95% 
confidence intervals for proportions in study V. In this study, the agreement among 
various diagnostic levels was measured using kappa. The statistical significance for all 
analyses was set at 5%.  
 
4.4 Ethical considerations 
The Regional Committee for Medical Research Ethics in Western Norway (REK Vest) 
and the Ethics Committee of SNNPRS Health Bureau in Ethiopia approved the study 
protocol. Household heads, TB suspects and PTB patients were interviewed after 
informed verbal consent was obtained, and the information from each interviewee was 
kept confidential. Government officials at various levels and community leaders were 
consulted and permission obtained before the start of field data collection.  
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5. Main Findings 
5.1 DOTS expansion, case notification and treatment outcomes (Paper I) 
19971 tuberculosis patients, 11138 (55.8%) males and 8819 (44.2%) females were 
registered between 1994 and 2001. Forty-six per cent (n=9232) of the patients were 
smear-positive cases. Overall, 18687 (93.6%) patients were registered as new cases. The 
proportion of women among registered TB patients remained at the range of 40-45% 
across the years. The proportion of women among patients older than 45 years was 
significantly lower (31%; 95%CI 29-33) compared to those below 45 (46%; 95%CI 45-
47). Case notification increased from 49/105 population in 1994 to 106 in 1996, 110 in 
1998 and 123 in 1999; then declined to 113 and 73 in 2000 and 2001, respectively. The 
proportion of expected smear-positive incident cases notified increased from 45% in 
1994 to 116% in 1999, and declined to 67% in 2001. 
 
The number of health institutions providing DOTS increased from two in 1994 to 10 in 
1997, 30 in 1999 and 41 in 2001, raising the population coverage by DOTS to 31%, 
58% and 75% respectively. The proportion of patients treated with SCC increased from 
7% in 1994 to 27% in 1998, 58% in 1999, and 97% in 2001. Simultaneously, treatment 
success for new smear-positive TB patients increased from 38% in 1994 to 56% in 
1998, 70% in 1999 and 73% in 2000 (χ2trend, p<0.001). Default rate declined from 38% 
in 1994 to 30% in 1998, 20% in 1999 and 18% in 2000 (χ2trend, p<0.001). Treatment 
failure decreased from 5% in 1994 to 1% in 2000. The proportion of reported deaths 
remained unchanged over years with some variations in the range of 2-5%. Patients 
treated at peripheral treatment centres had higher treatment success and lower default 
rates compared to the larger ones including the zonal hospital. 
 
5.2 Prevalence of smear-positive pulmonary tuberculosis (Paper II) 
This cross-sectional study was conducted with intent to estimate the prevalence of 
smear-positive pulmonary tuberculosis in a rural setting. Of 16697 adults aged >14 
years surveyed by home-to-home visit, 436 (2.6%) were symptomatic and gave sputum 
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samples for standard microscopy. Thirteen (3%) were positive for acid-fast bacilli, and 
the prevalence of smear-positive tuberculosis was 78/105 (95% CI 36-120). Twenty-four 
smear-positive cases identified through the existing health care delivery from the study 
area were on antituberculosis medication. The ratio of smear-positive cases on treatment 
to those newly detected by the survey was 2:1 adults suggesting that for every two cases 
of smear-positive TB on treatment during the survey, there was one case of undetected 
smear-positive TB in the community. Male to Female (M: F) ratio among patients on 
treatment was 2.43 (17/7), while that among patients detected by the survey was 0.86 
(6/7) (OR= 2.8; 95% CI 0.7-11.5). Patients detected by the survey were younger 
compared to those on treatment. There was no difference in other socio-demographic 
characteristics between patients on treatment and those not on treatment. 
 
5.3 Case-finding through community outreach programme (Paper III) 
With this study we intended to find out whether case finding through community 
outreach has an effect on case notification, pre-treatment symptom duration and 
treatment outcome of smear-positive tuberculosis in a rural setting. We compared these 
parameters between the intervention and control communities. During one-year period, 
159 and 221 cases of smear-positive tuberculosis were detected in the intervention and 
control groups, respectively. Case notification rates among all age groups in the 
intervention and control groups were 124.6/105 and 98.1/105 person-years, respectively 
(p=0.12). The corresponding rates among adults aged >14 years were 207/105 and 
158/105 person-years (p=0.09). Proportion of patients with >3 months symptom 
duration in the intervention communities was 41% compared with 63% in the control 
communities (p<0.001). Pre-treatment symptom duration in the intervention group 
showed a 55-60% decline over time compared with 3-20% reduction in the control 
group. 81% and 75% of patients successfully completed treatment in the intervention 
and control groups, respectively (p=0.12). 16% from the intervention group and 22% 
from the control group defaulted from treatment (p=0.11). One patient in the control 
group had treatment failure. Death rate was reported to be 3.1% in the intervention 
group and 3.2% in the control group (p=0.49). 
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5.4 Treatment adherence among smear-positive patients (Paper IV) 
This study explored factors predicting treatment adherence among smear-positive PTB 
patients diagnosed and registered in a zonal hospital. Of 404 new smear-positive PTB 
patients registered, 43% (n=174) were women. 21% (n=83) of the patients had 
treatment follow-up at Hossana hospital whereas, 43% (n=169) and 36% (n=139) were 
treated at the health centres and health stations respectively. 81 (20%) patients defaulted 
from treatment while 310 (77%) successfully completed treatment. 91% of treatment 
interruption occurred during the continuation phase. In Cox regression model, 
controlling for the potential predictor variables, distance from home to treatment centre 
(HR=2.97; p<0.001), age >25 years (HR =1.71; p=0.02) and necessity to use public 
transport to get to treatment centre (HR=1.59; p=0.06) remained independent risk 
factors for defaulting from treatment. It was possible to trace and advise 74 of the 81 
defaulters to resume medication. The main reasons given by 45% of the patients for 
defaulting from treatment were related to physical access (TB clinic too far from home, 
could not afford transport cost, and too tired to walk to the treatment centre). Mistaken 
sense of cure, loss of hope in the medication and inadequate knowledge about treatment 
duration were also among the reasons mentioned by the patients. 
 
5.5 Quality control of sputum microscopic examinations for AFB (Paper V) 
With the aim to evaluate the agreement in the readings of sputum smears for AFB 
between the diagnostic centres and the reference laboratories, 2209 slides, of which 
54% were positive and 46% negative, were collected from the peripheral diagnostic 
centres.  The regional laboratory team reread the slides, and 95 of these slides were 
found to be discordant and sent to the central reference laboratory. Considering the final 
reading at the central reference laboratory as a gold standard for the true smear result, 
both the sensitivity and specificity of the peripheral diagnostic laboratories was 96.8%, 
and the positive and negative predictive values were 97.3% and 96.2 % respectively. 
While the average false-reading at the peripheral laboratories in the region was 3.2% 
(range 0-5.1), there was a high degree of agreement (96.8%) between the readings at the 
peripheral diagnostic laboratories and the final reading (Κ = 0.936, SE=0.008). The 
proportion of false-positive slides declined from 4.4% in 2000 to 2.3% in 2001 and to 
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1.5% in mid-2002 (χ2trend =4.33; p=0.038). However, there was a no significant 
reduction of false-negatives: 3.9% in 2000, 2.4 in 2001 and 2.6 in 2002 (χ2trend =1.39; 
p=0.238). Nine zones took part in the quality control in 2000, six in 2001 and three in 
2002. 
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6. Discussion 
6.1 Methodological considerations 
6.1.1 Study design and sample size 
This study uses different designs, and each design has its own strengths and limits. The 
choice of an epidemiological study design depends on the research question under 
investigation, cost, time and feasibility 127. Descriptive study designs, such as cross-
sectional surveys, do not show temporal relationship between exposure and disease, and 
one cannot make causal inference from the findings. However, such studies are useful 
for public health planning, priority setting and resource allocation as they provide 
valuable information on health status, disease burden and health care needs of a 
population. Also, the findings may lead to formulating a testable epidemiological 
hypothesis. 
 
Studies on the prevalence of smear-positive TB (Paper II) and quality control of sputum 
microscopy for AFB (Paper V) employed cross-sectional study designs. The estimated 
size of the problem would help evaluating the TB control programme (TB prevalence 
survey) and the performance of the peripheral laboratories (quality control of sputum 
microscopy) if repeated at certain intervals. The results would also enable programme 
managers and clinicians to plan and carry out evidence-based interventions. The 
descriptive study design may answer the research questions under investigation: What is 
the prevalence of smear-positive TB? And, what is the level of agreement in the 
readings of sputum AFB microscopy between the diagnostic centres and the reference 
laboratories? 
 
We used observational analytic study designs to assess trends in expanding DOTS and 
treatment outcomes (Paper I), and to find out factors predicting treatment non-
completion (Paper IV). Such designs allow simultaneously examining multiple 
aetiologic factors for a single outcome (case-control) or multiple outcomes for a single 
exposure (cohort). Paper I used several approaches: retrospective cohort analysis (for 
example treatment outcome between those on SCC vs. those on LCC), case-control 
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analysis (for example, predictor variables for treatment success and default) and cross-
sectional comparison (for example case-notification for men vs. women), and compared 
the results across the years. The strength of such retrospective study designs depends on 
the quality and completeness of available data. This particular study was valuable in 
describing the trend in case-notification, smear-conversion and treatment outcomes over 
the years. It also described the trends on the expansion of DOTS. Nearly 20% of the 
patients did not have their outcome record. To increase validity of our results, all 
patients with missing outcome record were analysed as defaulters, and yet there was an 
increasing trend in treatment success and decrease in default and failure rates over the 
years. 
 
To test multiple predictors for treatment, a prospective cohort design was chosen (Paper 
IV). The prospective design allowed recording of potential risk factors for defaulting 
from treatment at the beginning of the study. As a result, the risk of recall bias, which is 
an inherent problem of retrospective study designs, is considered. Also, it reduced time 
and cost of tracing and interviewing cases and an equal number of controls that 
successfully completed treatment within the same period. However, this approach has 
some limits. For example, default rates were not compared in relation to events during 
treatment such as drug side effects and care provider-patient interactions, which could 
influence patient’s decision to continue treatment. Such factors cannot be recorded at 
the beginning of the study, and a combined approach may have yielded better results. 
Overall, and despite inherent limits that I shall discuss later, both case-control and 
cohort study designs can be used to test epidemiological hypothesis.  
 
Intervention studies are most desirable in epidemiological research as far as issues of 
cost, feasibility and ethics are sufficiently addressed 127, 128. Randomisation distributes 
all known and unknown baseline factors equally between the intervention and control 
groups. This makes it easier to compare the groups and enhances validity of the results. 
Paper III employed a cluster-randomised trial to find out whether case finding through a 
village outreach programme improved case-notification rate, pretreatment symptom 
duration and treatment outcome for smear-positive TB. The unit of randomisation was 
the community since such interventions cannot be allocated to individuals for practical 
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reasons as well as because of issues related to ethics and “contamination” 129, 130.  The 
knowledge of baseline values of the outcome and stratification or matching of the 
clusters before randomisation based on the baseline values would have added strength 
to the study. However, the number of clusters included was large enough for 
unrestricted randomisation, and both groups had comparable baseline characteristics.  
 
Sample size determines the power of a study and thus, the need for adequate sample size 
to discern a valid statistical association cannot be overemphasised. The papers in this 
thesis have taken sample size into account in their respective designs.  Papers I and V 
analysed the available data as a whole and the number of patients evaluated was large 
enough for multiple comparisons. In Paper II, for practical and logistic reasons, we 
limited our study to eight kebeles (clusters) that were randomly selected, and all 
households in the selected kebeles were surveyed. In most cluster sample surveys, the 
number of clusters is expected to be more than this to sufficiently represent the study 
population. However, the design effect calculated from the study data was 1.04, 
showing there was no significant inter-cluster variation in the study area. In the 
community randomised trial (Paper III), the number of clusters needed in each group 
was determined for the detection of 50% increase in case notification rate in the 
intervention group. However, the increase after the intervention was 31%, and this 
increase could not achieve statistical significance (P=0.09). An increase in the number 
of clusters in each wing may have increased the power to detect the effect of the 
intervention on case notification rate, if it exists. Apart from this, the sample was large 
enough for the comparison of pretreatment symptom duration and treatment outcome 
between the groups. 
 
6.1.2 Internal validity 
The validity of an epidemiological study is determined by whether the findings reflect 
the true relationship between the exposure and the outcome. In other words, it is 
important to find out whether and to what extent alternative explanations such as 
chance, bias, or confounding accounted for the observed association 127.  
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6.1.2.1 Chance 
Chance refers to the likelihood that sampling variability (random error) accounted for 
the observed association. The role of chance is assessed by performing test of statistical 
significance or by estimating the confidence interval of the effect 131.  We addressed the 
role of chance by performing appropriate statistical tests and estimating the confidence 
intervals. For example, in the intervention study (Paper III), the ratio of case-
notification rate in the intervention group to that in the control group was 31% and the 
difference in the weighted means between the groups was 47/100,000. However, this 
estimate lacks precision since the 95% confidence interval of the difference was 
between –27 and 123. This range crosses the null value (zero) and thus, we cannot 
exclude chance as a likely explanation for the observed result. The P value for this 
association was 0.09. In epidemiological research, P value of less than or equal to 0.05 
shows, by convention, the association is statistically significant 127, 131. Sampling error 
could be reduced and precision improved by increasing sample size.  As discussed 
earlier, the precision of the estimated difference in case-notification would have been 
improved by increasing the study size.  
 
6.1.2.2 Selection bias 
Selection bias is a systematic error that occurs when individual subjects are 
differentially enrolled into the study. In the treatment adherence study (Paper IV), there 
would be a risk of selecting cases and controls using non-comparable criteria if 
defaulters and non-defaulters were selected and analysed retrospectively with regard to 
possible predictor variables. For example, more controls than cases could have been 
selected from areas near the study hospital, and this could have spuriously 
overestimated the association between defaulting from treatment and distance to 
treatment centre. Such bias is unlikely in this cohort study as the potential exposure 
variables (including distance) were recorded before treatment outcome was known, and 
the groups were followed over time until they completed treatment, defaulted or 
otherwise.  
 
In the study on the quality control of sputum microscopy (Paper V), sampling bias in 
selecting slides for rechecking is potentially unavoidable. Technicians at peripheral 
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laboratories may keep slides with good quality stains and readings, and this may 
overestimate the agreement between the readings at the peripheral centres and that in 
the reference laboratories. Also, diagnostic centres that send slides for external quality 
assurance are likely to be better performers than those ones that do not send slides for 
quality check. Therefore, the high agreement between the peripheral and reference 
laboratories may be an overestimate.  
 
 
6.1.2.3 Information Bias (misclassification) 
Information or observation bias is a systematic error that results when information is 
differentially obtained from different study groups. Interviewer bias, recall bias and 
differential misclassification in ascertainment of exposure or disease, are the common 
forms of information bias.  Interviewer bias is of concern in the cohort (Paper IV) and 
intervention (Paper III) studies that employed interview questionnaires to get 
information on the potential exposure factors and outcome measures, respectively. In 
Paper IV, the prospective design of this study has allowed recording of potential risk 
factors for defaulting from treatment before the outcome was known, and the outcomes 
were measured not based on interviews. As a result, the risk of both interviewer and 
recall biases, which are inherent problems of case-control and retrospective cohort study 
designs, are considered. In Paper III, measurement variation in symptom duration 
among the interviewers might undermine the true effect of the intervention. To 
minimise measurement errors, questionnaires were standardised and pretested. Besides, 
the interviewers received proper training and they were blinded about the expected 
outcome measures to avoid measurement bias. 
 
 Bias because of loss to follow-up is unavoidable in Paper I, where there was no 
information on treatment outcome for nearly one-fifth of the cohort. Patients with 
missing information may be different from those for whom treatment outcome was 
recorded. Analysis of baseline social and demographic characteristics as well as 
treatment regimen did not show any difference between the groups, however. In line 
with the WHO/IUATLD recommendations, patients with missing outcome record in our 
study were all analysed as defaulters. Some of these patients may have been 
misclassified as defaulters only because of lack of information on their treatment status. 
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Such non-differential misclassification often dilutes the effect towards the null value. In 
paper IV, bias due to loss to follow-up was minimal as less than 1% of patients were 
lost to follow-up due to transfer out.  
 
There is a potential risk of differential misclassification in the study on the quality 
control of sputum microscopy (Paper V) where the knowledge of readings at the 
peripheral laboratories may influence the readings at the reference laboratory. Slides 
read as “positive” may be more vigorously searched for bacilli while those labelled 
“negative” may not. However, the rechecking in this particular study setting was 
performed under blinded condition, and the likelihood of such bias is small. 
 
6.1.2.4 Confounding 
Confounding is “a mixing of the effect of the exposure under study on the disease with 
that of a third factor. This third factor must be associated with the exposure and, 
independent of that exposure, be a risk factor for the disease” 127. Confounding can 
overestimate, underestimate or change the direction of the observed association, and 
must always be accounted for. For example, in the study on TB case finding (Paper III), 
some areas may have more educated people than other areas and, independent of area of 
residence, educated people are more likely to seek medical care for their symptoms and 
to seek care earlier. Also, the incidence of TB may differ from place to place, and 
independent of place, incidence determines case notification. Such baseline differences 
need to be accounted for in the design or analysis of epidemiological studies. The 
papers in this thesis have tried to control for confounding in the design (Paper III) and 
analysis (Papers IV and I) using randomisation and multivariate analysis, respectively.  
 
6.1.3 External validity 
External validity refers to whether the findings of an epidemiological study can be 
generalised to other populations. This study was conducted in a rural setting in southern 
Ethiopia that is typical of rural Ethiopia. However, variations in TB prevalence (Papers 
II & III), TB programme performance (Papers I &V), and treatment adherence (Paper 
IV) within the country, limits the generalisability of the results. Similarly, as all papers 
except Paper-I, focused on smear-positive pulmonary TB, we need more studies to find 
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out whether the findings of for example, predictors of treatment adherence can be 
applicable to other forms of TB. 
 
6.2 Discussion of main findings 
The success of a TB control programme depends on its ability to detect as many cases 
as possible and successfully treat them, reduce transmission and prevent drug resistance. 
DOTS is the current global strategy to achieve these goals 56. In this study, there was an 
increase in case notification rate and treatment success, which corresponds with the 
decentralisation and expansion of DOTS in the area.  The regional TLCP began DOTS 
in the zonal hospital followed by more health institutions every year. Such a gradual 
scale-up was important in securing the necessary means and in gaining experience to 
deal with emerging challenges.    
 
Case notification rate (CNR) nearly tripled between 1994 and 1999 and then levelled-
off despite an increase in the number of diagnostic and treatment centres. There are two 
alternative explanations for the increase. The most likely explanation is improved and 
decentralised diagnostic services resulting in registering large number of backlog cases 
in the first five years of DOTS. An increase in the incidence of active TB, fuelled by the 
HIV epidemic, might also explain this trend. Stabilisation in the observed CNR after 
1999 may suggest that an increase in case detection has been offset by a decrease in the 
incidence of active TB. 
 
Meanwhile, there was a promising progress towards the WHO/IUATLD recommended 
target of 85% treatment success for new smear-positive TB cases. Treatment success 
nearly doubled between 1994 and 2000 from 38% to 73%. Simultaneously, default rate 
decreased by more than a half (from 38% to 18%) between the respective years. The 
trend observed confirms the finding of other studies 58, 59 that DOTS works well in 
resource-constrained settings with low overall health coverage. The scale-up in DOTS 
fostered increased coverage by SCC, improved access to care through decentralisation 
of the service and improved patient follow-up, which in turn increased favourable 
treatment outcome. This implies the challenge of low-case detection and treatment 
success rates faced by most TB programmes may be overcome if existing opportunities 
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could be explored and carried out. One such opportunity used in our study setting was 
decentralisation of diagnostic and treatment services to the existing health services. 
 
On the other hand, this study has identified two key areas of programme weakness. 
First, improving the record keeping should be a priority as treatment outcomes were not 
recorded for about one-fifth of the patients. Further, 94% of the patients were registered 
as new cases, suggesting that some retreatment cases were classified as new. Second, 
portion of smear-positive TB patients who had follow-up sputa examined for AFB was 
low, although it has increased over the years. The importance of patient follow-up with 
sputum examinations cannot be overemphasised in the era with imminent threat of 
MDR-TB. 
 
The load of TB in a population may be estimated using various methods, each with their 
strengths and limits. Besides economic analysis of the global burden of disease (for 
example DALYS), some epidemiological approaches can help to measure the TB 
problem in a community. In rich countries with well-developed health care institutions, 
most active cases of TB are detected. Thus, health institution-based case notifications 
give an accurate estimate of TB incidence. On the other hand, case-notification from 
health institutions in resource-constrained settings often lacks completeness and 
consistency because of low health service coverage, inadequate diagnostic network and 
weak disease notification mechanisms. 
 
ARI calculated from tuberculin surveys, is another epidemiological tool useful in 
estimating the TB incidence and prevalence 132. Prevalence of active TB may also be 
estimated using mass miniature radiography (MMR) followed by sputum microscopy 
133-135. Both approaches are effective, but financial constraints and demand for expertise 
limit their use in poor countries. In Ethiopia, the last tuberculin survey was conducted 
fifteen years ago 136. Alternative approaches are therefore critical for estimating the 
prevalence and to oversee progress in TB control efforts. 
 
This study estimated the prevalence of smear-positive pulmonary TB in a rural district 
using symptom inquiry followed by sputum microscopy for AFB. The results show that 
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for every two cases of confirmed smear-positive TB on treatment, there was one case of 
undetected infectious TB in the community. Though the prevalence was lower than 
expected 137, it was higher than that reported from other African countries 103. In 
addition, more men were identified before the survey and were on treatment, whereas 
the ratio of men to women was similar in the survey. Besides the possibility of real 
gender difference in TB epidemiology 138-140, this finding suggests possible existence of 
gender differentials in access to health care, access by women being less 141, 142. 
 
Estimating TB prevalence using symptom inquiry and sputum microscopy is a simple 
and cheap technique. Such a method could bridge the information gap on the size of TB 
in resource-constrained settings. However, this method has some limits. It would only 
identify cases that report their symptoms. In addition, because of atypical clinical 
manifestations among HIV co-infected patients, some may not report their symptoms 
and, even if they report, the chance of smear-positivity is lower. As a result, this method 
should be considered only when studies with more accurate results, like tuberculin 
surveys and combined MMR with symptom inquiry and sputum microscopy are 
technically or logistically impossible. Under such circumstances, use of clinical 
algorithm with sputum microscopy may help to improve this tool to better estimate TB 
prevalence. 
 
The NTLCP manual for laboratory technicians recommends rechecking of a sample of 
routine slides to ensure the quality of sputum microscopy in the diagnostic centres 143. 
Rechecking of routine slides could be used interchangeably or with proficiency testing- 
monitoring of microscopists by sending centrally prepared panel of stained smears to 
peripheral laboratories. Although the former is more laborious, it represents the routine 
performance 144. This study was based on routine rechecking, and documented a good 
agreement between readings in the peripheral laboratories and that in the reference 
laboratories. Further, the extent of false readings declined over three-year period. 
Unfortunately, many diagnostic centres were not involved in the EQA and further, the 
number of zones and health institutions taking part in the programme decreased from 
year to year. It is unclear how those laboratories that do not send slides for quality-
check perform. As a result, the study findings might not represent the overall 
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performance in the region. Revitalising the quality assurance within the region should 
be a priority. 
 
With our study design, it was not possible to estimate the exact degree of discordance 
between the diagnostic and reference laboratories, as quantification was not part of this 
exercise. The NTLCP has recently changed the guideline to include quantification as 
part of sputum microscopy 91. Nevertheless, quantification does not have implications 
for case management. As far as patient management is considered, the finding of 97% 
agreement between the peripheral and final readings is encouraging. However, the 3.2% 
false-positive reading is too high and warrants further intervention. Expansion of the 
quality control scheme to all peripheral laboratories with regular supervisory visits, 
provision of timely feedback and regular refresher training programmes are issues for 
consideration. 
 
Case finding is one of the major challenges in TB control 100, 101. The current WHO and 
IUATLD guidelines underline case finding through sputum microscopy among 
symptomatic TB suspects reporting to health institutions 66. However, individual, socio-
cultural, biomedical and environment reasons could influence case finding. Improved 
diagnostic setting and procedures play an important role in case finding. Such efforts 
yield better results only if complemented by mechanisms to improve access to these 
services by the patient.  Further, many patients in rural settings present to diagnostic and 
treatment centres long after the active disease has occurred 96, 99, 104, 145. This study 
sought to test an alternative approach to case finding- case finding through a village 
outreach programme. The findings show the intervention improved the speed, but not 
the extent of case detection for smear-positive TB.  
 
As some patients with active TB may not report to the diagnostic and treatment 
services, we should consider new approaches for active case finding. The approaches 
for active case finding include MMR, periodic symptomatic case screening and 
household contact screening. Periodic symptomatic case screening and MMR for active 
case-finding were reported to be less effective than expected in middle- and high-
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income settings 146-150. One of the arguments was that many infected individuals 
develop active disease before the next screening. Further, it has been concluded that 
90% of smear positive TB cases present with symptoms and most seek treatment from 
health services 151. This assertion may not hold true for resource-constrained settings 
where studies show that many smear-positive TB cases had not been on treatment 137, 
152-156. Yet, there appears to be no consensus on the role of active case finding in low-
income settings. Many disparaged it because of increased workload on the health 
services and cost implications, while others believe that it is cost-effective in countries 
with high prevalence, low case detection and moderate to high treatment completion 157. 
Nevertheless, many agree that current case detection rates are inadequate and need to be 
improved 100, 101. 
 
This study was conducted in a typical rural setting. Though most smear-positive TB 
patients sought medical care from a public health service at a certain point during their 
illness, there was a long delay before diagnosis and treatment. Half of the population 
would have to travel more than two hours to get care in a public health institution. 
Private clinics are nearly non-existent, and delays in diagnosis and treatment occur 
while seeking care from alternative health care providers such as traditional healers. To 
increase basic health service coverage by reducing the access gap, the government has 
recently embarked on an initiative called “health service extension package”.  This 
package caters for a community-based approach. Thousands of health extension agents 
have been identified and trained since recently. These new front-line cadres of health 
might play an excellent role in improving TB case-finding and case-holding under the 
DOTS programme. 
 
 
 TB treatment aims to cure the patient and eventually break transmission of the bacilli. 
In this mainly rural setting, one-fifth of the registered smear-positive TB cases failed to 
complete treatment. Only half of the population live within reach of a health institution 
in two-hour walking distance 158, and  72% of patients in our study cohort came from 
within this circle. Among patients that came from areas outside this circle, half of them 
failed to complete treatment. As such, the main predictors of treatment non-completion 
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relate to physical access to treatment centre. Most patients interrupted treatment during 
the continuation phase. 
 
Defaulting from treatment is required to fall below 10% to achieve treatment success of 
85%, one of the health related indicators of the millennium development goals 22. 
Decentralisation of treatment follow-up to community health posts and improved 
patient-provider communication may reduce the extent of this problem. 
 
6.3 Implications of the study findings 
TB programme managers, policy makers and researchers need to analyse trends, 
challenges and opportunities on the ground to design proper interventions within a local 
context. Some of the challenges that this thesis identified include many patients with 
undiagnosed TB, long delay in diagnosis, deficiencies in diagnostic quality control, high 
rate of treatment non-completion and incomplete recording of treatment outcomes. 
Decentralised care under the DOTS programme, community-based approaches for case 
detection and case holding, and a policy environment that fosters community-based 
health extension programme are among the opportunities to be explored further.  
 
Trend analysis is important in finding out the burden of TB and how good the control 
efforts are. Therefore, it should be an integral part of programme planning and 
evaluation. Our study further showed improved case finding and reduced diagnostic 
delay in diagnosis of infectious TB cases through a community outreach programme. 
Therefore, managers and policy makers should consider community-based TB case 
finding as one of the ingredients of the health extension package. Such initiatives may 
yield better results if complemented by continuous quality assessment and improvement 
of diagnostic services. As part of improving case detection rate, external quality 
assessment of AFB microscopy should be made a compulsory exercise in all diagnostic 
laboratories.  
 
It has been encouraging to note increasing treatment success, mainly because of decline 
in default rate. However, treatment success was 74% and less than the 85% target. 
Further, treatment non-completion was high. The main cause influencing treatment 
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completion was availability of treatment centre. I recommend decentralising TB 
treatment to community health posts. Such move should also include training on record 
keeping, distinguishing between new and retreatment cases and follow-up sputum 
microscopy.  
  
6.4 Areas for further research 
There is scarcity of population-based data on the prevalence and incidence of TB in 
Ethiopia. Fifteen years have passed since the nation-wide tuberculin survey was done 
and the TB epidemiology may have changed since then. A simple technique of 
symptom inquiry and sputum microscopy used in this study should be refined and 
improved.  
 
The study on case finding through village outreach programme proved to be successful 
in reducing pretreatment symptom duration. However, despite a notable effect size, the 
difference in case notification between intervention and control groups was not 
statistically significant. Larger studies in multiple settings should be conducted. It is 
advisable that such studies also include cost-effectiveness analysis and baseline case 
notification rates to measure an independent effect of the intervention. 
 
For treatment adherence, a design that combines recording of potential predictor factors 
at the beginning and retrospective recording of events during treatment may help to 
understand the interplay of reasons that determine treatment adherence. Future research 
in this area should also explore the role of such interventions as decentralisation of 
treatment follow-up to community health posts and improved patient-provider 
communication. Peer-encouragement mechanisms such as forming “TB clubs” 82, 159 
have shown promising results, and may be worth testing at a broader scale.  
 
Unfortunately, we were not allowed to screen patients for HIV. Therefore, it was not 
possible to find out the effect of HIV on case notification rate (Paper III) and treatment 
compliance (Papers III & IV). In Paper IV, less than half of the patients volunteered for 
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HIV screening, and as a result, we were not able to find out how much HIV status 
influenced treatment interruption in our study setting.  Future studies may yield better 
results if the data are disaggregated by HIV status. 
 
7. Conclusions and recommendations 
 This thesis addresses some important areas in tuberculosis control in resource-limited 
settings. Trends in case notification and treatment outcomes were assessed. These 
parameters represent proxy indicators for programme performance and may be used to 
oversee TB control efforts. Further, considering the shortage of resources in many 
developing settings, a simple method to estimate the prevalence of smear-positive TB is 
recommended.   
 
The results of routine quality-check of AFB microscopy showed a promising trend that 
need to be strengthened. Unfortunately, the study showed that many laboratories are not 
taking part in the EQA of AFB microscopy, which suggests a need for revitalising this 
initiative. 
 
A community randomised trail on case finding through a village outreach programme 
proved to be successful in reducing diagnostic delay and it may improve case detection. 
Such intervention may easily be carried out with the new health extension package.  
 
In this study, some TB registers contained incomplete data. And, treatment follow-up 
with sputum microscopy was not done for more than one-third of smear-positive TB 
patients. Further, nearly one-fifth of the infectious TB cases interrupted treatment.  
 
Based on these conclusions I suggest the following recommendations:  
 
Recommendations for research: 
• Data for the analysis of trends in TB case detection or notification, and treatment 
outcomes could easily be obtained from unit or district registers; such data should be 
used to evaluate how existing control programme has been performing. 
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• Symptom inquiry plus sputum AFB microscopy may serve as an alternative tool for 
estimating prevalence of smear-positive TB, especially for programme impact 
evaluation purposes in resource-constrained set-ups.  
• Approaches to intensify case finding such as that through village outreach 
programmes may speed up the detection of infectious cases and should be evaluated 
in a broader scale.  
• Interventions to improve treatment adherence, such as decentralisation of treatment 
follow-up to community health posts, improved patient-provider communication 
and peer-encouragement mechanisms like TB clubs should be explored further.   
• Besides EQA of sputum AFB microscopy through rechecking of routine slides, 
periodic proficiency testing might help in assessing the microscopists in the 
diagnostic laboratories. 
 
Operational recommendations: 
• TB programme staff should receive proper training on case classification, treatment 
monitoring, record keeping and outcome recording.  
• Follow-up sputum microscopy should be strengthened to monitor patient progress 
for all smear-positive cases under treatment because of the risk of MDR-TB. 
• Diagnostic laboratories should keep and send slides for EQA of sputum smear 
microscopy. As such, continuous on the job training of laboratory staff is important 
to improve the diagnostic capacity. 
• Health promotion activities need to be an integral component of TB case finding and 
case holding plans. 
 
Policy recommendations: 
• Decentralising TB case finding and treatment to health posts may improve case 
notification and treatment compliance. 
• Community-based TB case finding should be one of the major components of the 
health extension package. 
• The quality control scheme for sputum AFB microscopy should involve all 
diagnostic laboratories and be supplemented by proficiency testing. 
• Evaluating the TB programme should involve not only assessing trends in case 
notification and treatment outcomes but also estimating trends on disease prevalence 
and incidence using simple methods.  
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